moxidectin / Generic mfg. - LARVOL DELTA

Activity of antifilarial drugs on microfilaremia in the treatment of loiasis: a systematic review. (PubMed, Parasit Vectors) - "Antifilarial drug efficacy against L. loa microfilaremia varies by dosage and treatment duration, with IVM and DEC demonstrating rapid, high efficacy but presenting safety concerns for hypermicrofilaremic individuals. ALB and MBZ show efficacy with extended treatment but are slower acting. Further research is needed to optimize treatment regimens and assess clinical outcomes beyond microfilaremia reduction."

Journal • Review

Efficacy of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) chewable tablets in the prevention of Borrelia burgdorferi transmission from infected Ixodes scapularis in dogs. (PubMed, Parasit Vectors) - "The laboratory studies described herein confirm that a single dose of lotilaner, at the minimum effective dosage of 20 mg/kg, administered as Credelio Quattro, in combination with moxidectin, praziquantel, and pyrantel or Credelio, is effective for the prevention of transmission of B. burgdorferi from infected I. scapularis for a full month in dogs."

Journal • Infectious Disease • Inflammatory Arthritis • Lyme Disease

Identification of potential mediators of moxidectin-induced developmental toxicity using network toxicology and structure-based analyses. (PubMed, Ecotoxicology) - No abstract available

Journal

Simparica Trio® kills Ctenocephalides felis on dogs and provides month-long protection against the transmission of Dipylidium caninum. (PubMed, Parasit Vectors) - "The efficacy provided by Simparica Trio against C. felis at the minimum dosage of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, and 5 mg/kg pyrantel (as pamoate salt) prevented D. caninum infection in dogs for 1 month."

Journal • Gastrointestinal Disorder • Infectious Disease

Safety and efficacy assessment of a chewable tablet containing sarolaner, moxidectin, and pyrantel in the treatment of Angiostrongylus vasorum in dogs. (PubMed, Vet Parasitol) - "Compared to the pre-treatment faecal larvae counts a geometric mean percent reduction of 96.7 % was observed on Day 30 and 99.1 % on Day 60 in the SMP treated group. Both in the experimental and in the field study, SMP as a chewable tablet was well tolerated and resulted in a high efficacy against adult A. vasorum infections after a single treatment."

Journal • Infectious Disease

Progress towards enabling access to moxidectin for onchocerciasis elimination programme (ASTMH 2025) - No abstract available

Infectious Disease

Using the new guideline for diagnosing anthelmintic resistance of gastrointestinal nematodes to different chemical components in sheep in the Rio Grande do Norte State, Brazil. (PubMed, Rev Bras Parasitol Vet) - "The faecal egg count reduction test (FECRT) was carried out to evaluate the pre- and post-treatment of anthelmintics, including albendazole, closantel, disophenol, ivermectin, levamisole, monepantel, moxidectin and trichlorfon, using the new classification criteria to analyze the results of an FECRT, which defined three possible classifications: susceptible, resistant and inconclusive...Two drugs (trichlorfon and monepantel) proved to be highly effective in treating gastrointestinal nematodes, presenting CI varying from 98 to 100% and 97 to 100%, respectively. Gastrointestinal nematodes from sheep raised in the in the Rio Grande do Norte State, Brazil are susceptible to the active principles trichlorfon and monepantel."

Journal

P-glycoprotein-9-mediated multidrug tolerance in Caenorhabditis elegans. (PubMed, Parasit Vectors) - "These results provide the first direct evidence that PGP-9 is necessary for multidrug tolerance in C. elegans, independently of amphid structural defects and NHR-8 regulation. These findings uncover a novel mechanism supporting drug resistance and highlight PGP-9 as a potential therapeutic target to improve ML treatments."

Journal

Moxidectin combination therapies for lymphatic filariasis-36-month follow-up. (PubMed, Lancet Infect Dis) - No abstract available

Journal

Treatment acceptability study following pilot community-based mass drug administration of moxidectin for onchocerciasis in Twifo Atti-Morkwa, Ghana (ASTMH 2025) - "As moxidectin will be distributed for the second time in August 2025, this research provides critical operational insights to support the training and community engagement activities prior to the MDA. The findings of this study are anticipated to support the overarching objective of eliminating onchocerciasis in Ghana and advancing progress toward the WHO Neglected Tropical Disease roadmap's 2030 elimination target."

Late-breaking abstract • Infectious Disease

Moxidectin versus ivermectin mass drug administration for the control of onchocerciasis and other neglected tropical diseases in Angola: a cluster-randomised trial (ASTMH 2025) - No abstract available

Clinical • Infectious Disease

Findings from an acceptability study following pilot community-based mass drug administration of moxidectin for onchocerciasis in Ghana. (ASTMH 2025) - No abstract available

Infectious Disease

Momentum project in Ghana: learnings from the first implementation of moxidectin as an alternative tool for onchocerciasis mass drug administration in Twifo Atti Morkwaa district (ASTMH 2025) - No abstract available

Infectious Disease

113 - From Pilot to Scale: Implementing Moxidectin Where It Is Needed to Support Countries' Onchocerciasis Elimination Efforts (ASTMH 2025) - "It will also explore MDGH's strategic next steps and potential pathways for regulatory, manufacturing, and policy support.The session will be particularly relevant to national NTD programs, policymakers, researchers, global health organizations and donors working towards onchocerciasis elimination. #NTDs#Elimination#Modeling#SocialScience"

Infectious Disease

Baseline assessment of ivermectin acceptability prior to the rollout of moxidectin mass drug administration for onchocerciasis control in Twifo Atti-Morkwa, Ghana (ASTMH 2025) - "Study results informed the rollout of moxidectin in January 2025. Study outcomes will contribute to the broader goal of onchocerciasis elimination."

Infectious Disease

Efficacy of moxidectin plus albendazole for lymphatic filariasis and onchocerciasis; follow-up of a large community safety study in a co-endemic area (ASTMH 2025) - P3 | "These data indicate that treatment received during MDGH-MOX-3002 resulted in complete clearance of Mf in 98% of individuals with bancroftian filariasis and 89% of individuals with onchocerciasis. An updated analysis by unblinded treatment assignment (still masked at the time of abstract submission) will be presented at the meeting."

Clinical • Infectious Disease

Tolerability of novel drug combination treatments for onchocerciasis (two doses, 6 months apart) (ASTMH 2025) - "A previous trial in Ghana showed that a co-administration of ivermectin (I), diethylcarbamazine (D) and albendazole (A) reduces the number of viable adults by about 40%. In a new randomized, blinded trial we compare the safety and efficacy of two standard doses of IA with IDA, moxidectin (Mox)A and MoxDA 6 months apart...From this ongoing study it can be concluded that after pre-treatment with ivermectin two doses of IDA, MoxA or MoxDA are as safe as IA, the standard treatment for onchocerciasis in areas co-endemic for lymphatic filariasis. The macrofilaricidal effects of these treatments will be assessed 18 months after the second experimental treatment."

Dermatology • Infectious Disease • Ophthalmology • Pruritus

Sustained clearance of Onchocerca volvulus skin microfilariae six months after ivermectin or moxidectin combination treatments (ASTMH 2025) - "Treatment arms included standard doses of ivermectin plus albendazole (IA, N=50), IA plus diethylcarbamazine (IDA, 55), Mox plus albendazole (MoxA, 50) and MoxA plus diethylcarbamazine (MoxDA, 54). Primary study outcomes (skin Mf and female worm fertility assessed by nodulectomy) will be assessed 18 months after a second dose of experimental treatment. Any feasible oral treatment that is superior to ivermectin or IA for achieving sustained Mf clearance or sterilization of adult worms could significantly accelerate onchocerciasis elimination in Africa."

Infectious Disease • Ophthalmology

Moxidectin: insights from the first round of MDA with Moxidectin for Onchocerciasis in Ghana (ASTMH 2025) - No abstract available

Infectious Disease

Moxidectin: results from an initial clinical trial in Lymphatic Filariasis (ASTMH 2025) - No abstract available

Clinical • First-in-human

21 - New Drugs for Treatment of Filarial Infections (ASTMH 2025) - "The drugs presented during the symposium (Corallopyronin A, Oxfendazole, Emodepside, Moxidectin and a re-purposed antibiotic, fusidic acid) are in various stages of development, from transition between preclinical development and Phase I to Phase II or Phase III clinical trials. An initial clinical trial using Moxidectin in combination with Albendazole alone or with Albendazole and Diethylcarbamazine for treatment of lymphatic filariasis has been carried out to evaluate the efficacy of the different combinations. Moxidectin, with its confirmed efficacy for the treatment of onchocerciasis has been used for the first time for mass drug administration in Ghana.#Vaccinology#ChildHealth#InfectiousDisease#Prevention#NewDrugs#ClinicalTrials"

Infectious Disease

ANTHELMINTIC THERAPIES FOR PARAFILAROIDES DECORUS PNEUMONIA IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS). (PubMed, J Zoo Wildl Med) - "There was no difference between treatment groups and changes in clinical scores on the basis of clinical signs, nor was there a difference between treatment groups and change of P. decorus presence. There is insufficient evidence to indicate that oral fenbendazole or subcutaneous moxidectin is superior for parasitic pneumonia therapy due to P. decorus in CSL."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

A pilot study on the potency of injectable vs. oral moxidectin formulation to suppress strongyle egg excretion in horses at twice lower dose. (PubMed, Helminthologia) - "On day 35 (P<0.001) and 42 (P<0.05) post treatment, the mean effi cacy was signifi cantly higher in Group IT as compared to Group OT. The present study contributes to the existing knowledge and providing more information on the use of injectable MOX solution for the treatment of strongylid infection in horses."

Journal • Infectious Disease • CLEC7A

Characterization of SPTLC2 as a key driver promoting microglial activation and energy metabolism reprogramming after ischemic stroke through bulk and single-cell analyses combined with experimental validation. (PubMed, Cell Biol Toxicol) - "Our study highlights SPTLC2 as a critical mediator of microglial activation and metabolic reprogramming in ischemic stroke, providing a foundation for developing novel therapeutic strategies targeting SPTLC2 to improve stroke outcomes."

Journal • Cardiovascular • Ischemic stroke • Metabolic Disorders • FLI1

Analyses of emerging macrocyclic lactone resistance: Speed and signature of ivermectin and moxidectin selection and evidence of a shared genetic locus. (PubMed, PLoS Pathog) - "We demonstrate that ivermectin selected lines show emerging moxidectin resistance, underpinned by a shared genetic locus of resistance. Finally, we speculate that key differences in the resistance phenotype between ivermectin and moxidectin selected lines relate to differences in the inheritance of resistance within this shared locus, with ivermectin resistance manifesting as dominant trait while moxidectin resistance appears to be recessive."

Journal